Equity
€25,342 from €162,036 in 2022
Equity fell by 84% in 3 years.
TAMIPHAR
Lifetime
20 annual accounts with figures on one time axis, 35 filings since 1991peak €752,758 (2013)
€752,262▲ 2.7%
lowest -€85,531 (2007)
-€11,311▲ €58,462
peak €162,036 (2022)
€25,342▼ 30.9%
€2.4m▲ 0.2%
peak 10.7 FTE (2013)
8.6 FTE▲ 1.2%
Board5 names since 2021
4 directorsPARGEFI SA and 3 others
Owners
50%BLUESTONE
Documentsfilings and deeds
15-10-202676 days late
2025financial year
Loss of €11,311Purpose change · Amendment of the articles 15-01Equity from €36,653 to €25,342Cash from €45,216 to €100,347
Key points
from the 2025 annual accountsLosses
-€136,694 in three years
Every financial year from 2023 to 2025 closed with a loss. 2024 was the heaviest.
Debts
€2.4m 99% of the balance sheet
Financial debts 1%Suppliers 50%Taxes and wages 5%Other 45%
Of this, €2.4m falls due within a year.
Staff
9 employees on 31-12-2025
In 2025, 3 people joined and 4 left.
Filings
35 annual accounts 76 days
Latest accounts filed late: after the legal deadline.
Position in the sector
1.0%
Lower solvency than 86% of companies in retail trade. Sector median 36.2% · 5,068 companies.
Checked score
51
Fair
Financially stronger than 18% of micro companies in retail trade (NACE 47)
Probability in this band: 1.5% to 4.2%
Bankruptcy probability within 12 months
2.2% Moderate
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,275 companies (NACE 47, micro).
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 2.9%
01-2025: 2.9%● unchanged vs 12-2024
02-2025: 3.0%▲ +0.1 percentage points vs 01-2025
03-2025: 3.3%▲ +0.3 percentage points vs 02-2025
04-2025: 3.3%● unchanged vs 03-2025
05-2025: 3.3%● unchanged vs 04-2025
06-2025: 3.4%▲ +0.1 percentage points vs 05-2025
07-2025: 3.8%▲ +0.4 percentage points vs 06-2025
08-2025: 4.7%▲ +0.9 percentage points vs 07-2025
09-2025: 5.4%▲ +0.7 percentage points vs 08-2025
10-2025: 6.4%▲ +1.0 percentage point vs 09-2025highest value
11-2025: 2.5%▼ -3.9 percentage points vs 10-2025
12-2025: 2.5%● unchanged vs 11-2025
01-2026: 2.5%● unchanged vs 12-2025
02-2026: 2.5%● unchanged vs 01-2026
03-2026: 2.8%▲ +0.3 percentage points vs 02-2026
04-2026: 2.8%● unchanged vs 03-2026
05-2026: 2.8%● unchanged vs 04-2026
06-2026: 2.9%▲ +0.1 percentage points vs 05-2026
07-2026: 2.9%● unchanged vs 06-2026
08-2026: 4.0%▲ +1.1 percentage points vs 07-2026
09-2026: 4.6%▲ +0.6 percentage points vs 08-2026
10-2026: 2.2%▼ -2.4 percentage points vs 09-2026lowest value
11-2026: 2.2%● unchanged vs 10-2026lowest value
Financial strengthWeak
Score breakdown
raises risk
Equity €25,342 (1.0% of total assets)
Last filed accounts filed 76 days late; 3 of the last 3 accounts late
Sector: Retail trade (NACE 47)
lowers risk
Founded in 1991
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 20% of them on solvency, 7% on liquidity, 30% on profitability and 16% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the moderate class on 30-06-2025, 2.4% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 974 companies had the same profile as TAMIPHAR has now. Each dot stands for 3 companies, two years later.
92.9%
were still trading
4.4%
stopped another way
2.3%
went bankrupt
Another 0.4% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of TAMIPHAR itself: 2.2% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 974 companies, not a prediction for TAMIPHAR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €1,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.31 (0.28 in 2024), below 1. Short-term debt is 98.2% and cash 4.1% of total assets. 99% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Seven signals.
lowers riskraises risk
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
1819202122232425
2018 to 2025 · latest year -€11,311
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 13% of 5068 sector peers (2025).
NBB · sector comparisonPosition among 5068 sector peers
Solvency
better than 13%
← weakest
strongest →
raises risk · 2025 accounts filed 76 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 15-10-2026, 76 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
76 days late
2024
71 days late
2023
92 days late
2022
221 days late
2021
239 days late
2020
89 days late
2019
122 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 130 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 1 November (4 of the last 5 accounts filed within 128 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
Shares in 2 companies, KITALPHAR and COMPAGNIE FINANCIERE ET IMMOBILIERE DE LA DYLE
Board & ownershipRecent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0443793509
Purpose change · Amendment of the articles
“1.l'exploitation d'officines pharmaceutiques dans le respect des règles édictées par l'Ordre des…” (deed in French) · General meeting of 27-12-2024 · Gazette deed
3 directors appointed, 1 resignation
Resignation: PARGEFI (managing director) · Appointments: BLUESTONE (managing director), Serge Ransart (managing director) and ENVERGURE INVEST · Permanent representatives: Paul Ransart and Charles Ransart · General meeting of 18-05-2022 · Gazette deed
New establishment in Wavre
PHARMACIE DE LA DYLE, Rue Charles Jaumotte 4
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| TAMIPHAR Lasne | €2.5m | €752,262 | 1.0% | 8.6 |
| PHARMA & FLO Namur | €2.6m | €746,861 | 57.9% | 7.6 |
| PHARMACIE TILMAN Durbuy | €2.5m | €832,338 | 15.5% | 7.3 |
| PHARMACIE HENRY Pont-à-Celles | €2.9m | €899,098 | 47.2% | 8.1 |
| EXTRA-PHARMA Kapellen | €3.1m | €765,107 | 18.2% | 8.7 |
| HOLSBEEK BRECHT - SINT -LENAERTS Brecht | €2.4m | €747,579 | 26.1% | 9.2 |
| PHARGEST Profondeville | €1.8m | €716,867 | 48.9% | 7.8 |
These companies have the same main activity as TAMIPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.8m and €3.1m, founded between 1976 and 1999.
Official details
Source: KBO- Status
- Active since 28-03-1991Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment units
- 2.052.363.6121380 Lasne, since 16-04-1991
- 2.154.817.7821360 Perwez, since 01-01-2006and 1 other
- Financial year end
- 31 December
- Peppol
- Reachable since 20-10-2025
Annual accounts 2025
- ≈ €2.7mestimated
- €2.5m▼ 0.3%
- Employeeson 31-12-2025
- 9▼ 10.0%
- Filing
- Filed on 15-10-2026
Insights on TAMIPHAR
TAMIPHAR has existed since 1991. The gross margin grew from €260,232 in 2006 to €752,262 in 2025 and staff from 3.9 to 8.6 full-time equivalents.
The gross margin has grown every year since 2021.
In August 2022, the Official Gazette published the appointment of Serge Ransart as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about TAMIPHAR
- What is the company number of TAMIPHAR?
- The company number of TAMIPHAR is 0443.793.509. The VAT number is the same number with BE in front: BE 0443.793.509.
- Where is TAMIPHAR based?
- The registered office is at Rue de la Bachée 84, 1380 Lasne.Company details
- What does TAMIPHAR do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of TAMIPHAR?
- TAMIPHAR is a public limited company (NV).
- When was TAMIPHAR founded?
- TAMIPHAR was founded on 28-03-1991.
- Is TAMIPHAR still active?
- Yes, TAMIPHAR is an active enterprise in the KBO register.
- How many employees does TAMIPHAR have?
- TAMIPHAR had an average of 8.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of TAMIPHAR?
- The turnover in financial year 2025 is ≈ €2.7m. This figure is estimated from the gross margin of €752,262 and 47 comparable companies (NACE 477). It probably lies between €2.0m and €4.2m.
- Is TAMIPHAR profitable?
- In financial year 2025, TAMIPHAR made a loss of €11,311.
- Where can I find the annual accounts of TAMIPHAR?
- TAMIPHAR filed 35 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of TAMIPHAR due?
- TAMIPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.